Compare Alcon AG (ALC) vs Atomera Incorporated (ATOM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Atomera Incorporated — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while Atomera Incorporated trades at $6.9 (market cap $284.76M). The key difference: Alcon AG is far larger — about 114.8× Atomera Incorporated's market cap, and Alcon AG pays a 0.54% dividend while Atomera Incorporated pays none. Which is the better fit depends on your goals.
| ALC | ATOM | |
|---|---|---|
Market Cap | $32.69B | $284.76M |
Sector | Health | Technology |
52-Week High | $92.22 | $12.11 |
52-Week Low | $62.02 | $1.99 |
Enterprise Value | $36.28B | $244.97M |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ATOM trades at $7.355, down 0.74% with bearish technical signals. The company shows severe financial distress with negative gross margins of -520.83% and net losses of -$20.17 million in 2025. Recent earnings misses and negative cash flow highlight operational challenges despite 100% analyst buy ratings. Technical indicators show bearish momentum with support at $7 and resistance at $8.
The outlook remains highly speculative given extreme financial losses and negative cash flow. Investment opportunity hinges on successful commercialization of GaN semiconductor technology, while risks include continued cash burn and failure to achieve revenue growth. The stock represents a high-risk bet on unproven technology execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Atomera Incorporated
Atomera is a semiconductor materials engineering company. Its Mears Silicon Technology (MST) is a patented thin film that enhances transistor performance, power efficiency, and cost for global chip manufacturers.
Read more on ATOM →
